Merck & CO INC.
Forward trial catalysts linked to MRK
CSA tracks 5 forward catalysts for Merck & CO INC. across 5 assets, spanning Phase 3, Phase 2/3. The nearest is a readout expected Oct 28, 2026 (day precision). Confidence across its tracked catalysts breaks down as 5 medium. Tracked indications include Carcinoma, Renal Cell, Renal Cell Carcinoma, Von Hippel-Lindau Disease, and 10 more.
MRK in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Merck & CO INC. has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
23 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| belzutifan | NCT04195750 | Phase 3 | Active, not recruiting | 2024-04-15 | Experimental | Merck Sharp & Dohme LLC | Carcinoma, Renal Cell |
| belzutifan | NCT04586231 | Phase 3 | Active, not recruiting | 2026-02-02 | Experimental | Merck Sharp & Dohme LLC | Carcinoma, Renal Cell |
| belzutifan | NCT04736706 | Phase 3 | Active, not recruiting | 2026-02-04 | Experimental | Merck Sharp & Dohme LLC | Carcinoma, Renal Cell |
| belzutifan | NCT05899049 | Phase 3 | Active, not recruiting | 2026-02-04 | Experimental | Merck Sharp & Dohme LLC | Carcinoma, Renal Cell |
| enlicitide decanoate | NCT07216482 | Phase 3 | Active, not recruiting | 2026-08-03 | Experimental | Merck Sharp & Dohme LLC | Hyperlipidemia |
| belzutifan | NCT05239728 catalyst | Phase 3 | Active, not recruiting | 2026-10-28 | Experimental | Merck Sharp & Dohme LLC | Carcinoma, Renal Cell |
| nemtabrutinib | NCT05624554 catalyst | Phase 3 | Active, not recruiting | 2027-05-19 | Experimental | Merck Sharp & Dohme LLC | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
| zilovertamab vedotin | NCT05139017 catalyst | Phase 2/3 | Recruiting | 2027-09-24 | Experimental | Merck Sharp & Dohme LLC | DLBCL; Diffuse Large B-Cell Lymphoma |
| enlicitide decanoate | NCT07821944 catalyst | Phase 3 | Not yet recruiting | 2027-11-26 | Experimental | Merck Sharp & Dohme LLC | Hyperlipidemia; Hypercholesterolemia |
| calderasib | NCT06345729 catalyst | Phase 3 | Recruiting | 2028-01-24 | Experimental | Merck Sharp & Dohme LLC | Non-small Cell Lung Cancer |
| enlicitide decanoate | NCT06492291 | Phase 3 | Active, not recruiting | 2028-10-13 | Experimental | Merck Sharp & Dohme LLC | Hypercholesterolemia |
| calderasib | NCT06997497 | Phase 3 | Recruiting | 2029-03-28 | Experimental | Merck Sharp & Dohme LLC | Colon Adenocarcinoma; Rectal Adenocarcinoma |
| zilovertamab vedotin | NCT06717347 | Phase 3 | Recruiting | 2029-07-02 | Experimental | Merck Sharp & Dohme LLC | Diffuse Large B-Cell Lymphoma |
| enlicitide decanoate | NCT06008756 | Phase 3 | Active, not recruiting | 2029-11-29 | Experimental | Merck Sharp & Dohme LLC | Arteriosclerosis; Hypercholesterolaemia |
| calderasib | NCT07190248 | Phase 3 | Recruiting | 2029-12-07 | Experimental | Merck Sharp & Dohme LLC | Non-small Cell Lung Cancer |
| belzutifan | NCT07489495 | Phase 3 | Recruiting | 2030-11-27 | Experimental | Merck Sharp & Dohme LLC | Carcinoma, Renal Cell |
| belzutifan | NCT07227402 | Phase 3 | Recruiting | 2032-02-27 | Experimental | Merck Sharp & Dohme LLC | Renal Cell Carcinoma |
| nemtabrutinib | NCT05947851 | Phase 3 | Recruiting | 2032-06-01 | Experimental | Merck Sharp & Dohme LLC | Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Chronic Lymphocytic; Small-Cell Lymphoma… |
| nemtabrutinib | NCT06136559 | Phase 3 | Recruiting | 2032-09-07 | Experimental | Merck Sharp & Dohme LLC | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
| calderasib | NCT07554339 | Phase 3 | Recruiting | 2032-12-15 | Experimental | Merck Sharp & Dohme LLC | Non-small Cell Lung Cancer |
| enlicitide decanoate | NCT07058077 | Phase 2/3 | Recruiting | 2033-12-04 | Experimental | Merck Sharp & Dohme LLC | Heterozygous Familial Hypercholesterolemia (HeFH) |
| belzutifan | NCT07405164 | Phase 3 | Recruiting | 2034-04-22 | Experimental | Merck Sharp & Dohme LLC | Von Hippel-Lindau Disease; Malignant Neoplasms |
| calderasib | NCT07431827 | Phase 3 | Recruiting | 2039-10-26 | Experimental | Merck Sharp & Dohme LLC | Non-small Cell Lung Cancer |
Every trial the CSA sample links to MRK's tracked assets.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →